Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Regeneron Q1 2026 net income falls 10% to $727m

AI-generated analysis

๐Ÿ“‰ GAAP net income declined 10% year-over-year to $727m in Q1 2026, compared to $809m in the prior period.

๐Ÿ’ฐ Non-GAAP net income increased 12% to $1.04bn, contrasting with the GAAP decline.

๐Ÿ“ˆ GAAP diluted EPS stood at $6.75 while non-GAAP diluted EPS grew 15% to $9.47 year-on-year.

๐Ÿ” Total revenue jumped 19% year-over-year to reach $3.6bn from $3.02bn in Q1 2025.

๐Ÿ’Š Dupixent global net sales rose 33% to $4.9bn while Eylea HD US net sales surged 52%.

๐Ÿงช R&D expenses climbed 16% to $1.54bn as the company invested in nearly 50 product candidates.

โš–๏ธ Acquired in-process research and development (IPR&D) expenses jumped significantly from $12m to $101.9m.

๐Ÿข SG&A expenses increased slightly by 2% to $648m, while cost of goods sold rose 40% to $373m.

๐Ÿ’ฌ CEO Leonard Schleifer highlighted double-digit growth despite continued investment in clinical development.

๐Ÿ‡บ๐Ÿ‡ธ Regeneron secured a new agreement with the US Government aimed at lowering drug prices and promoting balanced pricing with wealthy nations.

๐Ÿ”ฎ Management maintained unchanged guidance for 2026 R&D and SG&A expenses while raising GAAP gross margin expectations to 79-80%.

๐Ÿ›  Capital expenditure guidance was lifted to a range of $1.1bn-$1.3bn from the previous forecast.

โš–๏ธ Analysts maintain an average overweight rating with a mean price target of $880.7 for Regeneron stock.

Bullish Signals
  • Non-GAAP net income rose 12% to $1.04bn, demonstrating strong underlying profitability.
  • Total revenue increased 19% year-on-year to $3.6bn, significantly outperforming the GAAP earnings decline.
  • Dupixent global net sales recorded by Sanofi increased 33% to $4.9bn, highlighting continued growth in key franchise products.
  • Eylea HD US net sales jumped 52% to $468.4m, indicating robust demand for the company's ophthalmology portfolio.
  • Collaboration revenue advanced 24% to $1.9bn while other revenue more than doubled to $171.2m, diversifying income streams.
  • Regeneron raised its GAAP gross margin on net product sales to 80% from a prior range of 77% to 78%, improving operational efficiency.
  • The company invested in its pipeline with nearly 50 product candidates in clinical development and recently entered an agreement with the US Government to promote balanced pricing.
Risk Factors
  • GAAP net income fell 10% year-over-year to $727m despite strong top-line growth, indicating margin compression pressures.
  • Cost of goods sold surged 40% to $373m, while SG&A expenses increased 2% to $648m, contributing to the GAAP earnings decline.
  • The company lifted capital expenditures guidance to $1.1bn-$1.3bn, reflecting continued heavy investment in a pipeline of nearly 50 product candidates that may impact short-term profitability.
  • Acquired in-process research and development (IPR&D) expenses jumped significantly from $12m to $101.9m, inflating R&D costs by over $89m compared to the prior year.
  • The company entered into an agreement with the US Government aimed at lowering drug prices, which could create downward pressure on future revenue growth and profitability.
  • Regeneron's average price target is currently set at $880.7, suggesting analyst caution despite the reported double-digit revenue growth.
  • GAAP gross margin on net product sales is being adjusted upward to 79%-80% from 77%-78%, but this metric excludes high-investment R&D spending that depresses actual GAAP earnings.
Full Analysis
Regeneron Pharmaceuticals reported its first quarter 2026 financial results, revealing GAAP net income of $727 million, which represents a 10% decrease from the $809 million recorded in Q1 2025. Despite this decline on a GAAP basis, the company demonstrated stronger performance under non-GAAP metrics, with non-GAAP net income rising 12% to $1.04 billion compared to $928 million the prior year. Diluted earnings per share also diverged along these lines, showing GAAP EPS at $6.75 versus a 15% year-over-year increase in non-GAAP diluted EPS to $9.47 from $8.22. Revenue growth remained robust, with total revenue increasing 19% year-on-year to reach $3.6 billion from $3.02 billion in the previous period. This expansion was driven by collaboration revenue, which advanced significantly by 24% to $1.9 billion, and other revenue more than doubling to $171.2 million. Dupixent global net sales, recorded under Sanofi, climbed 33% to $4.9 billion, while Eylea HD US net sales surged 52% to $468.4 million. However, operating expenses increased as the company maintained its investment strategy, with R&D costs rising 16% to $1.54 billion and acquired in-process research and development (IPR&D) expenses spiking from $12 million to $101.9 million. In terms of guidance, Regeneron kept its forecasts for 2026 R&D and SG&A expenses unchanged while adjusting other outlooks. The company raised its GAAP gross margin on net product sales from the previously guided range of 77% to 78% up to a new target of 79% to 80%. Additionally, capital expenditures were lifted slightly to $1.1 billion to $1.3 billion from the prior guidance of $1.1 billion to $1.2 billion. CEO Leonard Schleifer highlighted that the quarter achieved strong double-digit growth on both the top and bottom line while investing in a pipeline of nearly 50 product candidates in clinical development, alongside recent progress on agreements with the US Government regarding drug pricing strategies.